CONTACT DERMATITIS, published by WILEY, is a leading international journal focused on the vital field of dermatology, particularly examining the diagnosis, treatment, and management of contact dermatitis and related skin conditions. With origins dating back to 1975 and a planned convergence period extending to 2024, this esteemed journal serves as a crucial resource for researchers, clinicians, and healthcare professionals dedicated to advancing knowledge in dermatological practices. In the latest rankings, it has achieved a commendable Q2 classification in Dermatology and Q3 classification in Immunology and Allergy for 2023, underscoring its significance within these dynamic fields. Moreover, it holds a notable ranking of #29/142 in Medicine & Dermatology and #130/233 in Medicine & Immunology and Allergy according to Scopus metrics, placing it in the top tier of scholarly publications. While the journal operates on a subscription basis, its comprehensive reviews, original articles, and insightful research findings are invaluable for pushing the boundaries of current dermatological and immunological knowledge. By fostering a deeper understanding of the complexities of skin reactions and their implications, CONTACT DERMATITIS plays a vital role in connecting research with clinical practice, making it an essential read for anyone engaged in the field.

Dermatopathology is a pioneering open-access journal dedicated to the field of skin pathology, published by MDPI in Basel, Switzerland. Since its inception in 2014, the journal has provided a vital platform for the dissemination of cutting-edge research, advancements, and clinical studies that aid in the understanding of dermatological diseases at the microscopic level. With its commitment to accessibility and wide-ranging contributions from international researchers, Dermatopathology serves as an essential resource for dermatologists, pathologists, and academics alike. The journal strives to foster innovative collaborations and enhance knowledge within the multidisciplinary sphere of dermatology and pathology, ensuring timely access to valuable information that can influence clinical practices and improve patient outcomes. Researchers are encouraged to submit their original articles, case reports, and reviews, contributing to the growing body of knowledge essential for advancing the field.

EXPERIMENTAL DERMATOLOGY, published by WILEY, is a leading journal in the fields of Biochemistry and Dermatology, with impressive rankings including Q1 status in both categories as of 2023. With its ISSN 0906-6705 and E-ISSN 1600-0625, the journal offers a reputable platform for disseminating cutting-edge research and insights into skin biology and related health issues. As a pivotal resource for professionals, researchers, and students alike, EXPERIMENTAL DERMATOLOGY includes a broad scope of topics, fostering a deeper understanding of dermatological conditions and enhancing new therapeutic strategies. The journal’s distinguished performance is highlighted by its Scopus rankings, which place it at the 91st percentile in Medicine-Dermatology and the 65th in Biochemistry. While not an open-access publication, the journal remains committed to ensuring the accessibility of crucial developments within the dermatological community worldwide, facilitating the advancement of both clinical practice and academic inquiry.

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, published by Wiley, is a prominent periodical in the field of dermatology, recognized by its Q2 quartile ranking in the 2023 dermatology category. With a dedicated focus on advancing knowledge in dermatological science, the journal publishes rigorous peer-reviewed research that encompasses a range of topics including clinical studies, research methodologies, and innovative treatment practices in dermatology. Its impact is reflected in its Scopus ranking, where it stands at #48 out of 142 in the medicine dermatology category, placing it in the top 66th percentile. Although not an Open Access journal, it serves as a critical resource for researchers, clinicians, and students alike, facilitating the dissemination of high-quality research findings and fostering a deeper understanding of dermatological conditions and treatments. With years of convergence from 2003 to 2024, this journal remains a vital platform for scholarly dialogue and discovery in dermatology.

Dermatologic Therapy is a leading peer-reviewed journal published by WILEY-HINDAWI that focuses on the multifaceted field of dermatology. Established in 1996 and continuing its profound impact into 2024, the journal has earned an impressive Q1 rating in Dermatology and ranks 11th out of 142 in the Scopus categorization, placing it in the 92nd percentile. With its headquarters in the United Kingdom, the journal's mission is to advance the understanding and treatment of skin diseases through the dissemination of high-quality research, reviews, and clinical information. Although not an open-access journal, it provides extensive access options to ensure that vital research reaches its audience. By leading scholarly discourse and innovation in dermatological treatments, Dermatologic Therapy serves as an essential resource for researchers, clinicians, and students dedicated to improving skin health worldwide.

CUTIS is a distinguished journal devoted to advancing the field of dermatology and related medical disciplines. Published by Quadrant HealthCom Inc, this journal has been a critical resource since its inception in 1970, traversing the landscape of skin health and medical practice through its engaging articles and research. With an ISSN of 0011-4162 and an E-ISSN of 2326-6929, CUTIS is indexed in Scopus, where it currently holds a rank of #101/142 in the Dermatology category, placing it in the 29th percentile, further affirming its relevance within the academic community. Although it is classified within the Q3 quartile in both Dermatology and Medicine (miscellaneous), CUTIS remains committed to publishing high-quality research that encompasses both innovative treatments and essential dermatological knowledge. The journal serves as an invaluable platform for researchers, practitioners, and students alike, providing critical insights and fostering discussions that enhance patient care and professional practice in the dermatology field.

The Indian Journal of Dermatology Venereology & Leprology (IJDL) is a premier open-access journal dedicated to the fields of dermatology, venereology, and leprology, published by SCIENTIFIC SCHOLAR LLC since 2004. With a rich historical background dating back to 1976, the journal has established itself as a reputable source for high-quality research and clinical advancements in these disciplines. The IJDL is recognized for its academic rigor, boasting a 2023 category quartile ranking of Q2 in Dermatology and Q3 in Infectious Diseases, indicating its significant contribution to these fields. With an accessible online platform, researchers, practitioners, and students alike can readily explore the latest studies, case reports, and reviews that address key issues affecting public health, particularly in India and beyond. The journal serves not only as a repository of valuable knowledge but also as a vital forum for the exchange of ideas, fostering collaboration and innovation among professionals dedicated to enhancing skin health and combating infectious diseases.

Dermatology Practical & Conceptual is a prominent open-access journal dedicated to advancing the field of dermatology through the dissemination of cutting-edge research and practical insights. Published by MATTIOLI 1885, this peer-reviewed journal has been committed to open access since 2015, ensuring that valuable information is readily available to researchers, healthcare professionals, and students worldwide. With a focus on innovative and practical approaches in dermatology, as well as its intersections with genetics, molecular biology, and oncology, the journal has established a strong academic presence, achieving a Q2 ranking in Dermatology and notable positions in related fields for 2023. Although its Scopus rankings indicate room for improvement in certain areas, such as genetics and molecular biology, the journal's commitment to quality and accessibility is evident in its engagement with contemporary research trends. The editors invite submissions that address practical challenges and novel methodologies, fostering a multidisciplinary dialogue that enhances dermatological practice and research. The journal operates from its base in Fidenza, Italy, and as it looks toward converged years from 2019 to 2024, it aims to further strengthen its influence and contribute significantly to the dermatological landscape.

JAMA Dermatology, an esteemed publication by the American Medical Association, is positioned at the forefront of dermatological research and clinical practice. With an ISSN of 2168-6068 and an E-ISSN of 2168-6084, this journal underscores a commitment to disseminating high-quality and impactful research within the field. Notably ranked Q1 in both Dermatology and Miscellaneous Medicine for 2023, JAMA Dermatology ranks among the top journals in its category, holding the impressive 3rd position out of 142 in Scopus's dermatology rankings, placing it in the 98th percentile. With converged years extending from 2013 to 2024, the journal emphasizes timely and critical advancements in dermatological science. Furthermore, as a champion of open access, it encourages a broad dissemination of knowledge, making essential research accessible to a wider audience. Researchers, professionals, and students alike will find JAMA Dermatology to be an invaluable resource for the latest findings, innovative therapies, and in-depth reviews that shape the future of dermatological health.

The Journal of Cutaneous Immunology and Allergy, published by FRONTIERS MEDIA SA in Switzerland, is an esteemed Open Access platform dedicated to advancing research in the intersecting fields of dermatology, immunology, and allergy. Since its inception in 2018, this journal has provided a vital resource for the dissemination of innovative research findings and critical reviews, enhancing our understanding of cutaneous conditions related to immune responses. Although currently classified in the Q4 quartile in both Dermatology and Immunology & Allergy categories as of 2023, the journal continues to strive for recognition within the scientific community, encouraging collaboration and knowledge sharing among researchers, clinicians, and experts. The journal boasts an E-ISSN of 2574-4593 and is committed to making high-quality research freely accessible to all, thus fostering greater insights into the complexities of skin-related immune disorders. Join us in this journey to explore the forefront of cutaneous research and contribute to the evolving dialogue in this dynamic field.